Forte Biosciences (FBRX) Share-based Compensation (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Share-based Compensation of $3.2 million for Q1 2026, up 96.11% year-over-year from $1.6 million in Q1 2025, and up 90.93% quarter-over-quarter from $1.7 million in Q4 2025.
Forte Biosciences (FBRX) Share-based Compensation (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Share-based Compensation for 11 consecutive years, with $3.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 96.11% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $7.8 million (up 99.87% YoY), while the FY2025 annual figure was $14.4 million, up 365.27% from the prior year.
- Share-based Compensation improved to $3.2 million in Q1 2026 per FBRX's latest filing, from $1.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $3.2 million in Q1 2026 and bottomed at $158000.0 in Q1 2022.
- Historically, Share-based Compensation has averaged $1.1 million across 5 years, with a median of $860000.0 in 2022.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 68.08% — and 2023, when it surged 455.06%.
- Forte Biosciences' Share-based Compensation stood at $860000.0 in 2022, then retreated by 9.3% to $780000.0 in 2023, then slipped by 10.64% to $697000.0 in 2024, then soared by 138.74% to $1.7 million in 2025, then jumped by 90.93% to $3.2 million in 2026.
- Business Quant data shows FBRX's Share-based Compensation at $3.2 million in Q1 2026, $1.7 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | 47.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.80 Mn |
| Jun 30, 2026 | 47.80 Mn |
| Mar 31, 2026 | 3.18 Mn |
| Mar 31, 2026 | 3.18 Mn |
| Dec 31, 2025 | 1.66 Mn |
| Dec 31, 2025 | 1.66 Mn |
| Sep 30, 2025 | 1.48 Mn |
| Sep 30, 2025 | 1.48 Mn |
| Jun 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 1.50 Mn |
| Mar 31, 2025 | 1.62 Mn |
| Mar 31, 2025 | 1.62 Mn |
| Dec 31, 2024 | 697,000.00 |
| Dec 31, 2024 | 697,000.00 |
| Sep 30, 2024 | 791,000.00 |
| Sep 30, 2024 | 791,000.00 |
| Jun 30, 2024 | 802,000.00 |
| Jun 30, 2024 | 802,000.00 |
| Mar 31, 2024 | 805,000.00 |
| Mar 31, 2024 | 805,000.00 |